Foresee Pharmaceuticals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	431.27	418.69	195.04	301.51	226.03
Revenue Growth (YoY)	3.01%	114.67%	-35.31%	33.39%	-1.91%
Cost of Revenue	137.06	178.89	81.07	25.54	50.95
Gross Profit	294.22	239.8	113.97	275.97	175.08
Selling, General & Admin	181.4	147.32	160.16	124.23	99.07
Research & Development	975.13	1,172	961.44	621.18	614.64
Operating Expenses	1,157	1,320	1,122	745.41	713.71
Operating Income	-862.32	-1,080	-1,008	-469.44	-538.63
Interest Expense	-5.57	-6.71	-2.85	-0.4	-0.68
Interest & Investment Income	18.17	28.28	23.53	8.34	3.53
Currency Exchange Gain (Loss)	-17.67	21.51	-2.32	23.35	-3.05
Other Non Operating Income (Expenses)	9.17	3.26	0.83	1.2	10.17
EBT Excluding Unusual Items	-858.2	-1,033	-988.45	-436.96	-528.66
Gain (Loss) on Sale of Investments	-	-	-	0.29	0.8
Gain (Loss) on Sale of Assets	-	-0.03	-0.2	-0.31	-0.13
Asset Writedown	-	-	-	-1.16	-
Other Unusual Items	-	0.28	0.01	-	-
Pretax Income	-858.2	-1,033	-988.64	-438.13	-527.99
Income Tax Expense	24.95	47.87	47.67	34.51	41.28
Net Income	-883.15	-1,081	-1,036	-472.64	-569.27
Net Income to Common	-883.15	-1,081	-1,036	-472.64	-569.27
Shares Outstanding (Basic)	155	137	127	118	117
Shares Outstanding (Diluted)	155	137	127	118	117
Shares Change (YoY)	12.80%	7.89%	7.82%	0.57%	15.74%
EPS (Basic)	-5.70	-7.87	-8.14	-4.00	-4.85
EPS (Diluted)	-5.70	-7.87	-8.14	-4.00	-4.85
Free Cash Flow	-845.19	-1,323	-933.84	-291.29	-220.19
Free Cash Flow Per Share	-5.46	-9.64	-7.34	-2.47	-1.88
Gross Margin	68.22%	57.27%	58.44%	91.53%	77.46%
Operating Margin	-199.95%	-257.90%	-516.63%	-155.70%	-238.30%
Profit Margin	-204.78%	-258.20%	-531.33%	-156.76%	-251.86%
Free Cash Flow Margin	-195.98%	-316.07%	-478.80%	-96.61%	-97.42%
EBITDA	-812.19	-1,016	-950.68	-429.72	-498.38
EBITDA Margin	-188.32%	-242.56%	-	-142.52%	-220.50%
D&A For EBITDA	50.13	64.2	56.95	39.72	40.24
EBIT	-862.32	-1,080	-1,008	-469.44	-538.63
EBIT Margin	-199.95%	-257.90%	-	-155.70%	-238.30%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.